Literature DB >> 9557744

Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs.

I V Alymova1, S Kodihalli, E A Govorkova, B Fanget, C Gerdil, R G Webster.   

Abstract

The immunogenicity and protective efficacy of formalin-inactivated influenza B/Memphis/1/93 virus vaccines propagated exclusively in Vero cells, MDCK cells, or embryonated chicken eggs (hereafter referred to as eggs) were investigated. Mammalian cell-grown viruses differ from the egg-grown variant at amino acid position 198 (Pro/Thr) in the hemagglutinin gene. The level of neuraminidase activity was highest in egg-grown virus, while MDCK and Vero cell-derived viruses possessed 70 and 90% less activity, respectively. After boosting, each of the vaccines induced high levels of hemagglutinin-inhibiting, neuraminidase-inhibiting, and neutralizing antibodies that provided complete protection from MDCK-grown virus challenge. Mammalian cell-derived virus vaccines induced serum antibodies that were more cross-reactive, while those induced by egg-grown virus vaccines were more specific to the homologous antigen. Enzyme-linked immunospot analysis indicated that cell-grown virus vaccines induced high frequencies of immunoglobulin G (IgG)-producing cells directed against both cell- and egg-grown virus antigens, whereas egg-grown virus vaccine induced higher frequencies of IgG- and IgM-producing cells reacting with homologous antigen and low levels of IgG-producing cells reactive with cell-grown viruses. These studies indicate that influenza B virus variants selected in different host systems can elicit different immune responses, but these alterations had no detectable influence on the protective efficacy of the vaccines with the immunization protocol used in this study.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557744      PMCID: PMC109684          DOI: 10.1128/JVI.72.5.4472-4477.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  The thiobarbituric acid assay of sialic acids.

Authors:  L WARREN
Journal:  J Biol Chem       Date:  1959-08       Impact factor: 5.157

2.  Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity.

Authors:  S Liang; K Mozdzanowska; G Palladino; W Gerhard
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

3.  Effect of protein adsorption on the surface charge characteristics of aluminium-containing adjuvants.

Authors:  R al-Shakhshir; F Regnier; J L White; S L Hem
Journal:  Vaccine       Date:  1994-04       Impact factor: 3.641

4.  Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man.

Authors:  R B Couch; R G Douglas; D S Fedson; J A Kasel
Journal:  J Infect Dis       Date:  1971-11       Impact factor: 5.226

5.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

6.  Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective.

Authors:  S Kodihalli; D M Justewicz; L V Gubareva; R G Webster
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs.

Authors:  A M Palache; R Brands; G J van Scharrenburg
Journal:  J Infect Dis       Date:  1997-08       Impact factor: 5.226

8.  Synthesis of 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid and detection of skin fibroblast neuraminidase in normal humans and in sialidosis.

Authors:  T G Warner; J S O'Brien
Journal:  Biochemistry       Date:  1979-06-26       Impact factor: 3.162

9.  Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero).

Authors:  E A Govorkova; N V Kaverin; L V Gubareva; B Meignier; R G Webster
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

10.  Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition.

Authors:  B E Johansson; E D Kilbourne
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

View more
  14 in total

Review 1.  The threat of avian influenza A (H5N1). Part IV: Development of vaccines.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-06-01       Impact factor: 3.402

Review 2.  Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.

Authors:  Nagendra R Hegde
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Advances in novel influenza vaccines: a patent review.

Authors:  Jae-Min Song
Journal:  J Microbiol       Date:  2016-05-27       Impact factor: 3.422

4.  Cell culture-derived flu vaccine: Present and future.

Authors:  Alberto Pérez Rubio; Jose María Eiros
Journal:  Hum Vaccin Immunother       Date:  2018-06-28       Impact factor: 3.452

5.  Quadrivalent cell culture influenza virus vaccine. Comparison to egg-derived vaccine.

Authors:  Alberto Pérez-Rubio; Julio Ancochea; Jose María Eiros Bouza
Journal:  Hum Vaccin Immunother       Date:  2020-04-07       Impact factor: 3.452

6.  Antimycotic-antibiotic amphotericin B promotes influenza virus replication in cell culture.

Authors:  Elisabeth Roethl; Manuela Gassner; Brigitte M Krenn; Ekaterina A Romanovskaya-Romanko; Helena Seper; Julia Romanova; Sabine Nakowitsch; Sanda Sturlan; Markus Wolschek; Alexej Sirotkin; Oleg Kiselev; Thomas Muster; Andrej Egorov
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

7.  Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs.

Authors:  Noriko Kishida; Seiichiro Fujisaki; Masaru Yokoyama; Hironori Sato; Reiko Saito; Hideyuki Ikematsu; Hong Xu; Emi Takashita; Masato Tashiro; Shinichi Takao; Takuya Yano; Tomoko Suga; Chiharu Kawakami; Miwako Yamamoto; Keiko Kajiyama; Hiroyuki Saito; Shin'ichi Shimada; Sumi Watanabe; Satomi Aoki; Katsuya Taira; Miyako Kon; Jih-Hui Lin; Takato Odagiri
Journal:  Clin Vaccine Immunol       Date:  2012-04-04

8.  Influenza A virus lacking M2 protein as a live attenuated vaccine.

Authors:  Shinji Watanabe; Tokiko Watanabe; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

9.  Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus.

Authors:  Chih-Jen Wei; Ling Xu; Wing-Pui Kong; Wei Shi; Kevin Canis; James Stevens; Zhi-Yong Yang; Anne Dell; Stuart M Haslam; Ian A Wilson; Gary J Nabel
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

10.  Development of high-yield influenza A virus vaccine viruses.

Authors:  Jihui Ping; Tiago J S Lopes; Chairul A Nidom; Elodie Ghedin; Catherine A Macken; Adam Fitch; Masaki Imai; Eileen A Maher; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  Nat Commun       Date:  2015-09-02       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.